RxDoctor Payments Data

Allan Moore, OD

Optometrist · Manchester, GANPI 1942296017

Payments from drug & device makers

$1,290in general payments, 2019–2025

Across 29 payments — averaging $44.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$315
  • Bausch & Lomb Americas Inc.$278
  • AbbVie$206
  • Coopervision Inc.$193
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$100
  • Sun Pharmaceutical Industries Inc.$71
  • plus $127 from 3 others

What the payments were for

  • Food & beverage$1,290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,290 in reported general payments places this provider in the 60th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$41,807
Medicare patients
331
Services billed
2,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine135$179,861
LumiganBimatoprost121$38,202
XiidraLifitegrast26$23,581
Cyclosporine24$21,897
CombiganBrimonidine Tartrate/Timolol31$6,229
Alphagan PBrimonidine Tartrate16$4,056
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$2,821
Prednisolone Acetate92$2,557
Timolol Maleate193$1,854
Ketorolac Tromethamine68$1,705
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha136$1,594
Latanoprost149$1,458
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat41$377
Ofloxacin31$359
ErythromycinErythromycin Base14$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$206$228,349303 claims
Bausch & Lomb Americas Inc.Xiidra$278$23,58126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Manchester

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →